Beryl Drugs Ltd (BERLDRG) is currently trading at 23.96 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Beryl Drugs Limited, based in Indore, India, is involved in the manufacture, sale, and export of branded and generic pharmaceutical formulations both locally and internationally. The company specializes in the manufacture of I.V. fluids, injectables, eye/ear drops, and veterinary products, reflecting a broad portfolio in its offering. Beryl Drugs has a strategic foothold in the pharmaceutical industry with WHO GMP-compliant manufacturing facilities, ensuring high standards in its production processes. With a robust portfolio, Beryl owns popular pharmaceutical brands such as BERI-CEF injection, F-Neuron, and Amplicillin INJ, which enhance its market presence. The company's commitment to quality is underscored by its ISO 9001:2000 certification, emphasizing its focus on high-quality healthcare product manufacturing.

Over the past 52 weeks, Beryl Drugs Ltd has traded between a low of ₹15.92 and a high of ₹27.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Beryl Drugs Ltd has a market capitalization of approximately 12.16. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Beryl Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 19.61 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 12.16 Cr, Beryl Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Beryl Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Beryl Drugs Ltd is 19.61. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.